Johns Hopkins Thoracic Oncology (@hopkinsthoracic) 's Twitter Profile
Johns Hopkins Thoracic Oncology

@hopkinsthoracic

World class patient care and research in lung cancer, esophageal cancer, mesothelioma, and all thoracic cancers

ID: 1262181220043165696

linkhttps://www.hopkinsmedicine.org/kimmel_cancer_center/centers/lung_cancer_program/ calendar_today18-05-2020 00:41:19

1,1K Tweet

1,1K Followers

140 Following

Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

#WLC25 Susan Combs Scott, MD Johns Hopkins Thoracic Oncology knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 & MARIPOSA trials) EGFR Resisters #lcsm PER

#WLC25 <a href="/SusanScottMD/">Susan Combs Scott, MD</a> <a href="/HopkinsThoracic/">Johns Hopkins Thoracic Oncology</a> knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 &amp; MARIPOSA trials) <a href="/EGFRResisters/">EGFR Resisters</a> #lcsm <a href="/gotoPER/">PER</a>
OncLive.com (@onclive) 's Twitter Profile Photo

A huge thanks to Benjamin Levy, of Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center, for stopping by during #WLC25 to talk all things ADCs in lung cancer! See our site for ADC insights and more! PER #gotoPER #lcsm onclive.com/conference/win…

A huge thanks to <a href="/benlevylungdoc/">Benjamin Levy</a>, of <a href="/HopkinsMedicine/">Johns Hopkins Medicine</a> and <a href="/hopkinskimmel/">Johns Hopkins Kimmel Cancer Center</a>, for stopping by during #WLC25 to talk all things ADCs in lung cancer! See our site for ADC insights and more! <a href="/gotoPER/">PER</a> #gotoPER #lcsm
onclive.com/conference/win…
Kellie N. Smith (@smithimmunology) 's Twitter Profile Photo

We developed a 3-gene signature to identify tumor-specific CD8 TIL, i.e. the cells targeted by #immunotherapy, from #singlecell data. Out now in Nature Communications. All data & code are public. Please use it! #WomenInSTEM #science #research #datascience #AI nature.com/articles/s4146…

Patrick Forde (@fordepatrick) 's Twitter Profile Photo

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

Cancer Research Institute (@cancerresearch) 's Twitter Profile Photo

📸 CRI Investigator Elsa Anagnostou of Molecular OncologyLab Johns Hopkins Thoracic Oncology presents Leveraging the cfDNA fragmentome to predict immunotherapy response, during #AACR25's Minisymposium - Liquid Biopsy: Circulating Nucleic Acids. AACR #Immunotherapy

📸 CRI Investigator <a href="/ValsamoA/">Elsa Anagnostou</a> of <a href="/MolecularOncLab/">Molecular OncologyLab</a> <a href="/HopkinsThoracic/">Johns Hopkins Thoracic Oncology</a> presents Leveraging the cfDNA fragmentome to predict immunotherapy response, during #AACR25's Minisymposium - Liquid Biopsy: Circulating Nucleic Acids. <a href="/AACR/">AACR</a> #Immunotherapy
Patrick Forde (@fordepatrick) 's Twitter Profile Photo

Open access & up to date review of immunotherapy for earlier stage lung cancer led by Dr. ⁦Colum Dennehy chief fellow ⁦Johns Hopkins Hematology and Oncology Fellowship⁩ & an all 🇮🇪 team out now! ⁦Trinity St James's Cancer Institute⁩ “Immunotherapy for resectable lung cancer” - Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Patrick Forde (@fordepatrick) 's Twitter Profile Photo

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

Out now &amp; open access in <a href="/NatureMedicine/">Nature Medicine</a> concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6
Patrick Forde (@fordepatrick) 's Twitter Profile Photo

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In <a href="/NEJM/">NEJM</a> today &amp; presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/